Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)

Cvetkovic‐Vega, Aleksandar; Urrunaga-Pastor, Diego; Soto-Becerra, Percy; Morales, Luis  Edgardo Figueroa; Fernández-Bolivar, Lizzete; Alvizuri-Pastor, Sergio; Oyanguren-Miranda, Martin; Vera, Ibeth Melania Neyra; Ramos, Elizabeth Emilia Carrillo; Sagástegui, Arturo A.; Macazana, Roxana Milagros Contreras; Rengifo, Diana  Elizabeth Lecca; Castro, Nikolai  Grande; Apolaya-Segura, Moisés; Maguiña, Jorge L.

doi:10.1016/j.tmaid.2022.102514

Cited by 3 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study predominantly consisted of females (90.6% and 95.3% for the non-infected and infected participants, respectively) as most participants enrolled were female nurses. Similarly, other studies investigating HCWs also reported higher proportions of female participants [ 19 , 57 , 58 ]. Several studies have shown that women generally exhibit a more substantial antibody response to vaccine as compared to men [ 55 , 57 , 58 , 59 , 60 ].…”

Section: Discussionsupporting

confidence: 52%

Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff

et al. 2023

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 had reported over 676 million cases by March 2023. The main aim of this study is to investigate whether the levels of anti-S and anti-N antibodies could precisely indicate the degree of protection against SARS-CoV-2 and affect the probability or time of contracting COVID-19. In this study, a serosurveillance study was conducted in healthcare workers (HCWs) at a regional hospital in Taiwan to evaluate their antibody levels based on infection and vaccination status. Of 245 HCWs enrolled, all have been vaccinated prior to infection. Of these, 85 participants were infected by SARS-CoV-2, while 160 participants were not infected at the time of blood sample collection. The level of anti-SARS-CoV-2 S antibody was significantly higher in the infected HCWs than in the non-infected participants (p < 0.001). It is worth noting that the mean duration between the administration of the last dose of the vaccine and the occurrence of SARS-CoV-2 infection was 5.61 ± 2.95 months. Our follow-up survey revealed that the non-infected group had significantly higher levels of antibodies compared to the infected group (all p < 0.001). In conclusion, this study suggests that the level of antibodies could serve as a reflection of the protective efficacy against SARS-CoV-2 infection. It has the implication for vaccine decision-making policies in the future.

show abstract

Section: Discussionsupporting

confidence: 52%

Investigating the Current Status of SARS-CoV-2 Antibodies in Hospital Staff

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Association of the seropositivity and titer of protective antibodies after two shot vaccination with sex, age, and residence of vaccinees were reported ambiguous PLOS ONE [35,36]. Age was often reported as a predictor of seropositivity in subjects who vaccinated with the BBIBP-CorV vaccine [13,35,37]. We found a 98.2% seropositivity after two shots of the BNT162b vaccine among immunocompromised individuals, including patients who received immunosuppressive therapy and PLWHA.…”

Section: Plos Onementioning

confidence: 66%

RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia

Batmunkh,

Otgonbayar,

Shaarii

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21–28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21–28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.

show abstract

“…High immunogenicity was identified among healthcare workers receiving a third booster dose of BNT after complete BBIBP vaccination. All participants were IgG seropositive to SARS-CoV-2 even though in a pre-booster measurement, a significant percentage of seronegativity was estimated [16] . Besides, participants reported a high occurrence of reactogenicity related to pain in the application site; however, no serious adverse events were identified.…”

Section: Discussionmentioning

confidence: 93%

“…We conducted a cross-sectional study among healthcare providers from several intermediate and high-level healthcare facilities of the Seguro Social de Salud del Perú - ESSALUD in Lima, Peru, from November 2021 and January 2022. The study population included participants from a research cohort enrolled previously through random stratified sampling (n=1,436 out of a source population composed of 2,539) to evaluate the SARS-CoV-2 humoral response after the second vaccine dose [16] . We included two-dose BBIBP-CorV vaccinated participants who presented a three-dose vaccination card at least 21 days passed since the vaccinees received their third dose schedule and provided written informed consent.…”

Section: Methodsmentioning

confidence: 99%

“…A similar relation was identified in BNT and ChAd vaccinees Xu et al, 2021; Favresse et al, 2021 Dec; Shrotri et al, 2021 Jul 31; Pilishvili et al, 2021 Dec 16;385 [11] , [12] , [13] , [14] , and in natural infections [15] . Anti-SARS-CoV-2 antibody seronegativity was estimated at 30% after four months of complete BBIBP vaccination [16] . In Peru, natural infections triggered by the circulation of B.1.1.7 (Alpha), B.1.351 (Beta), and C.37 (Lambda) variants in early 2021 during the second wave [17] , along with the extended primary vaccination that reached adult population in late 2021, did not prevent the transmission of B.1.617 (Delta) and B.1.529 (Omicron) [18] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation